iTeos to Participate in Upcoming Investor Conferences

Rhea-AI Summary

iTeos Therapeutics (Nasdaq: ITOS) has announced its participation in two major investor conferences in December 2024. The company will attend the 7th Annual Evercore HealthCONx Conference on December 3 in Coral Gables, FL, featuring a fireside chat at 9:35 AM ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4 in New York, NY, with a fireside chat scheduled for 11:30 AM ET.

Both events will include one-on-one investor meetings. The presentations will be available via live webcast on iTeos' website, with recordings accessible for approximately 30 days afterward.

News Market Reaction

-0.61%

1 alert

-0.61% News Effect

On the day this news was published, ITOS declined 0.61%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:

7^Th Annual Evercore HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: Tuesday, December 3, 2024
Time: 9:35 AM ET
Location: Coral Gables, FL

Piper Sandler 36^th Annual Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, December 4, 2024
Time: 11:30 AM ET
Location: New York, NY

A live webcast of the conference presentation will be available on the Investors section of the company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

For further information, please contact:

Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

FAQ

What investor conferences will iTeos (ITOS) attend in December 2024?

iTeos will participate in the 7th Annual Evercore HealthCONx Conference on December 3 and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.

When is iTeos' (ITOS) presentation at the Evercore HealthCONx Conference?

iTeos will present at the Evercore HealthCONx Conference on Tuesday, December 3, 2024, at 9:35 AM ET in Coral Gables, FL.

How long will iTeos' (ITOS) conference webcasts be available for replay?

The webcasts of iTeos' conference presentations will be available for replay for approximately 30 days following each presentation.

Where can investors watch iTeos' (ITOS) conference presentations?

Investors can watch the live webcasts of iTeos' presentations on the Investors section of the company's website at www.iteostherapeutics.com.